275 related articles for article (PubMed ID: 20140279)
1. Targeted therapy for advanced prostate cancer: Looking through new lenses.
Vogiatzi P; Cassone M; Claudio L; Claudio PP
Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
3. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
4. Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
DiPaola RS; Aisner J
Semin Oncol; 1999 Feb; 26(1 Suppl 2):112-6. PubMed ID: 10190792
[TBL] [Abstract][Full Text] [Related]
5. New drugs in prostate cancer.
Armstrong AJ; Carducci MA
Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
[TBL] [Abstract][Full Text] [Related]
6. New molecular targets in advanced prostate cancer.
Dawson NA
Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
[TBL] [Abstract][Full Text] [Related]
7. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
8. Novel targets and approaches in advanced prostate cancer.
Hadaschik BA; Sowery RD; Gleave ME
Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
10. Cellular immunotherapies for prostate cancer.
McNeel DG
Biomed Pharmacother; 2007 Jul; 61(6):315-22. PubMed ID: 17306498
[TBL] [Abstract][Full Text] [Related]
11. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
Basch EM; Somerfield MR; Beer TM; Carducci MA; Higano CS; Hussain MH; Scher HI;
J Clin Oncol; 2007 Nov; 25(33):5313-8. PubMed ID: 17925542
[TBL] [Abstract][Full Text] [Related]
13. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
Amato RJ; Teh BS; Henary H; Khan M; Saxena S
Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115
[TBL] [Abstract][Full Text] [Related]
14. Update on castrate-resistant prostate cancer: 2010.
Lassi K; Dawson NA
Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
[TBL] [Abstract][Full Text] [Related]
15. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.
Dorff TB; Quek ML; Daneshmand S; Pinski J
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1639-51. PubMed ID: 17134367
[TBL] [Abstract][Full Text] [Related]
16. Current controversies in the treatment of high-risk prostate cancer.
Mitchell RE; Chang SS
Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235
[TBL] [Abstract][Full Text] [Related]
17. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
18. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapies in castrate-resistant prostate cancer.
Lassi K; Dawson NA
Curr Opin Oncol; 2009 May; 21(3):260-5. PubMed ID: 19363343
[TBL] [Abstract][Full Text] [Related]
20. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
